You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 7, 2024

PRIMAXIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Primaxin, and when can generic versions of Primaxin launch?

Primaxin is a drug marketed by Merck and is included in three NDAs.

The generic ingredient in PRIMAXIN is cilastatin sodium; imipenem. There are sixteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cilastatin sodium; imipenem profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PRIMAXIN?
  • What are the global sales for PRIMAXIN?
  • What is Average Wholesale Price for PRIMAXIN?
Summary for PRIMAXIN
Drug patent expirations by year for PRIMAXIN
Drug Prices for PRIMAXIN

See drug prices for PRIMAXIN

Recent Clinical Trials for PRIMAXIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Merck Sharp & Dohme Corp.Phase 1
PfizerPhase 3
AstraZenecaPhase 3

See all PRIMAXIN clinical trials

Pharmacology for PRIMAXIN

US Patents and Regulatory Information for PRIMAXIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck PRIMAXIN cilastatin sodium; imipenem INJECTABLE;INJECTION 062756-001 Jan 8, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAMUSCULAR 050630-002 Dec 14, 1990 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Merck PRIMAXIN cilastatin sodium; imipenem INJECTABLE;INJECTION 062756-002 Jan 8, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAMUSCULAR 050630-001 Dec 14, 1990 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 050587-002 Nov 26, 1985 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 050587-001 Nov 26, 1985 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PRIMAXIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 050587-002 Nov 26, 1985 ⤷  Sign Up ⤷  Sign Up
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAMUSCULAR 050630-001 Dec 14, 1990 ⤷  Sign Up ⤷  Sign Up
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 050587-001 Nov 26, 1985 ⤷  Sign Up ⤷  Sign Up
Merck PRIMAXIN cilastatin sodium; imipenem POWDER;INTRAMUSCULAR 050630-002 Dec 14, 1990 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for PRIMAXIN

See the table below for patents covering PRIMAXIN around the world.

Country Patent Number Title Estimated Expiration
Croatia P940099 PROCESS FOR THE PREPARATION OF Z-2-ACYLAMINO-3-MONOSUBSTITUTED PROPENIC ACIDS AND THEIR ESTERS AND SALTS ⤷  Sign Up
Poland 125506 ⤷  Sign Up
Denmark 157399 ⤷  Sign Up
German Democratic Republic 145059 VERFAHREN ZUR HERSTELLUNG EINER ANTIBAKTERIELLEN ZUSAMMENSETZUNG ⤷  Sign Up
New Zealand 190994 Z-2-ACYLAMINO-3-MONOSUBSTITUTED PROPENOATES ⤷  Sign Up
Finland 792282 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for PRIMAXIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2666774 PA2020518,C2666774-2 Lithuania ⤷  Sign Up PRODUCT NAME: RELEBAKTAMAS, PASIRINKTINAI MONOHIDRATO PAVIDALU, SU IMIPENEMU IR CILASTATINU, PASIRINKTINAI NATRIO DRUSKOS PAVIDALU; REGISTRATION NO/DATE: EU/1/19/1420 20200213
2666774 122020000036 Germany ⤷  Sign Up PRODUCT NAME: RELEBACTAM, ODER RELEBACTAM IN FORM DES MONOHYDRATES, IMIPENEM UND CILASTATIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1420 20200213
2666774 20C1032 France ⤷  Sign Up PRODUCT NAME: RELEBACTAM OPTIONNELLEMENT SOUS FORME DE MONOHYDRATE, IMIPENEME ET CILASTATINE OPTIONNELLEMENT SOUS FORME DE SEL SODIQUE; REGISTRATION NO/DATE: EU/1/19/1420 20200217
2666774 CA 2020 00037 Denmark ⤷  Sign Up PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
2666774 2020024 Norway ⤷  Sign Up PRODUCT NAME: KOMBINASJON AV RELEBAKTAM EVENTUELT I FORM AV MONOHYDRAT, IMIPENEM OG CILASTATIN, EVENTUELT I FORM AV NATRIUMSALT; REG. NO/DATE: EU/1/19/1420 20200219
2666774 31/2020 Austria ⤷  Sign Up PRODUCT NAME: RELEBACTAM, GEGEBENENFALLS IN DER FORM DES MONOHYDRATS, IMIPENEM UND CILASTATIN, GEGEBENENFALLS IN DER FORM DES NATRIUMSALZES.; REGISTRATION NO/DATE: EU/1/19/1420 (MITTEILUNG) 20200217
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.